308 related articles for article (PubMed ID: 19455053)
21. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP
J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879
[TBL] [Abstract][Full Text] [Related]
22. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
23. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects.
Wolk R; Chen D; Clark RW; Mancuso J; Barclay PL
Clin Pharmacol Ther; 2009 Oct; 86(4):430-7. PubMed ID: 19587642
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of dalcetrapib.
Stein EA; Stroes ES; Steiner G; Buckley BM; Capponi AM; Burgess T; Niesor EJ; Kallend D; Kastelein JJ
Am J Cardiol; 2009 Jul; 104(1):82-91. PubMed ID: 19576325
[TBL] [Abstract][Full Text] [Related]
26. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].
Rensen PC; Jukema JW
Ned Tijdschr Geneeskd; 2008 May; 152(19):1088-90. PubMed ID: 18552062
[TBL] [Abstract][Full Text] [Related]
27. Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
[TBL] [Abstract][Full Text] [Related]
28. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Masson D
Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
[TBL] [Abstract][Full Text] [Related]
29. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
30. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
Gauthier A; Lau P; Zha X; Milne R; McPherson R
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
[TBL] [Abstract][Full Text] [Related]
31. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.
Hermann F; Enseleit F; Spieker LE; Périat D; Sudano I; Hermann M; Corti R; Noll G; Ruschitzka F; Lüscher TF
Thromb Res; 2009; 123(3):460-5. PubMed ID: 18789492
[TBL] [Abstract][Full Text] [Related]
32. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
33. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
34. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
[TBL] [Abstract][Full Text] [Related]
35. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
Forrest MJ; Bloomfield D; Briscoe RJ; Brown PN; Cumiskey AM; Ehrhart J; Hershey JC; Keller WJ; Ma X; McPherson HE; Messina E; Peterson LB; Sharif-Rodriguez W; Siegl PK; Sinclair PJ; Sparrow CP; Stevenson AS; Sun SY; Tsai C; Vargas H; Walker M; West SH; White V; Woltmann RF
Br J Pharmacol; 2008 Aug; 154(7):1465-73. PubMed ID: 18536749
[TBL] [Abstract][Full Text] [Related]
36. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
Sofat R; Hingorani AD; Smeeth L; Humphries SE; Talmud PJ; Cooper J; Shah T; Sandhu MS; Ricketts SL; Boekholdt SM; Wareham N; Khaw KT; Kumari M; Kivimaki M; Marmot M; Asselbergs FW; van der Harst P; Dullaart RP; Navis G; van Veldhuisen DJ; Van Gilst WH; Thompson JF; McCaskie P; Palmer LJ; Arca M; Quagliarini F; Gaudio C; Cambien F; Nicaud V; Poirer O; Gudnason V; Isaacs A; Witteman JC; van Duijn CM; Pencina M; Vasan RS; D'Agostino RB; Ordovas J; Li TY; Kakko S; Kauma H; Savolainen MJ; Kesäniemi YA; Sandhofer A; Paulweber B; Sorli JV; Goto A; Yokoyama S; Okumura K; Horne BD; Packard C; Freeman D; Ford I; Sattar N; McCormack V; Lawlor DA; Ebrahim S; Smith GD; Kastelein JJ; Deanfield J; Casas JP
Circulation; 2010 Jan; 121(1):52-62. PubMed ID: 20026784
[TBL] [Abstract][Full Text] [Related]
37. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
Johannsen TH; Frikke-Schmidt R; Schou J; Nordestgaard BG; Tybjærg-Hansen A
J Am Coll Cardiol; 2012 Nov; 60(20):2041-8. PubMed ID: 23083790
[TBL] [Abstract][Full Text] [Related]
38. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs.
Polakowski JS; King AJ; Campbell TJ; Nelson RA; Preusser LC; Kempf-Grote AJ; Marsh KC; Gintant GA; Cox BF; Mittelstadt SW
J Cardiovasc Pharmacol; 2009 Dec; 54(6):543-51. PubMed ID: 19770671
[TBL] [Abstract][Full Text] [Related]
40. Is high HDL cholesterol always good?
Olsson AG
Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
